We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · September 21, 2022

De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in IDH-Mutant Glioma

Cancer Cell

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Cell
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Cancer Cell 2022 Sep 12;40(9)939-956.e16, DD Shi, MR Savani, MM Levitt, AC Wang, JE Endress, CE Bird, J Buehler, SA Stopka, MS Regan, YF Lin, VT Puliyappadamba, W Gao, J Khanal, L Evans, JH Lee, L Guo, Y Xiao, M Xu, B Huang, RB Jennings, DM Bonal, MS Martin-Sandoval, T Dang, LC Gattie, AB Cameron, S Lee, JM Asara, HI Kornblum, TW Mak, RE Looper, QD Nguyen, S Signoretti, S Gradl, A Sutter, M Jeffers, A Janzer, MA Lehrman, LG Zacharias, TP Mathews, JA Losman, TE Richardson, DP Cahill, RJ DeBerardinis, KL Ligon, L Xu, P Ly, NYR Agar, KG Abdullah, IS Harris, WG Kaelin, SK McBrayer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading